Slide 1: 2012 Preliminary results
2012 Preliminary results 12 FEBRUARY 2013
Slide 2: Full year 2012 highlights
Full year 2012 highlights • Revenue € 828.3 million, up 8.7%. • Operating income (EBIT) € 167.0 million or 20.2% of sales, up 2.1%. • Net income € 118.5 million or 14.3% of sales, up 1.8%. • Acquisition of a portfolio of treatments for rare diseases in the USA. Recordati Rare Diseases Inc. operation
Slide 3: Main product sales
Main product sales Corporate products including orphan drugs now account for 42.8% of revenue (million Euro) 2012 2011 Change % Zanidip® (lercanidipine) 114.6 124.7 (8.1) Zanipress® (lercanidipine+enalapril) 49.3 41.6 18.6 Urorec® (silodosin) 32.7 19.8 65.8 Livazo® (pitavastatin) 16.3 6.8 139.9 Othe
Slide 4: A richer product portfolio
A richer product portfolio Urorec 4.0% Livazo 2.0% Other corporate products 8.0% Zanipress 5.9% Orphan drugs 9.2% Zanidip 13.8% Pharmaceutical chemicals 3.7% Subsidiaries’ local product Other revenue 1.7% portfolios 51.7% Entact®/Elopram® 5% (escitalopram/citalopram) ‐ Italy Tergynan® ‐ Russia & CIS
Slide 5: Composition of revenue
Composition of revenue New markets and new products drive growth (million Euro) 2012 2011 Change % Italy 214.7 217.7 (1.4) France 120.2 128.7 (6.6) Germany 70.9 66.2 7.1 Turkey 64.8 31.0 108.9 Portugal 33.9 34.4 (1.4) Spain 33.3 31.8 4.5 United Kingdom 5.6 7.6 (26.9) Other Western European countries
Slide 6: A growing presence in Eastern Europe and Turkey
A growing presence in Eastern Europe and Turkey Spain 4.2% Portugal 4.2% Turkey 8.1% UK 0.7% Germany 8.9% Other W. European countries 2.7% Russia, other CEE 9.6% USA 0.9% France 15.1% Other international sales 18.6% (sales to licensees and exports) Italy 27.0% Data: Full year 2012 Pharmaceutical rev
Slide 7: Full year 2012 results
Full year 2012 results Sales and earnings growth in line with guidance (million Euro) 2012 2011 Change % Revenue 828.3 762.0 8.7 Gross Profit 534.8 502.1 6.5 as % of revenue 64.6 65.9 SG&A Expenses 296,1 277.5 6.7 as % of revenue 35.7 36.4 R&D Expenses 63.4 56.0 13.3 as % of revenue 7.7 7.3 Other In
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 31 Dec 2012 31 Dec 2011 Change Cash and short‐term financial 38.4 105.2 (66.7) investments Bank overdrafts and short‐term loans (56.0) (13.6) (42.4) Loans – due within one year (8.1) (11.6) 3.5 Loans – due after one year (127.7) (135.7) 8.0
Slide 9: Comparison with financial projections
Comparison with financial projections 2012 targets achieved 2012 2012 (million Euro) Actual Targets Revenue 828.3 810‐830 Operating income (EBIT) 167.0 160‐170 Net Income 118.5 115‐120 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan